+Compare
MYGN
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
1.88B

MYGN Price Prediction, Myriad Genetics AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for MYGN with price predictions
08:00 PM EDT May 31, 2023

MYGN in upward trend: 10-day moving average moved above 50-day moving average on June 01, 2023

The 10-day moving average for MYGN crossed bullishly above the 50-day moving average on June 01, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 19, 2023. You may want to consider a long position or call options on MYGN as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MYGN just turned positive on May 19, 2023. Looking at past instances where MYGN's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

MYGN moved above its 50-day moving average on May 23, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MYGN advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for MYGN moved out of overbought territory on May 25, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MYGN broke above its upper Bollinger Band on May 23, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MYGN entered a downward trend on May 22, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MYGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.256) is normal, around the industry mean (25.070). P/E Ratio (0.000) is within average values for comparable stocks, (142.694). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (5.626). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (2.690) is also within normal values, averaging (52.813).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

A.I. Advisor
published Earnings

MYGN is expected to report earnings to fall 62.95% to -7 cents per share on August 03

Myriad Genetics MYGN Stock Earnings Reports
Q2'23
Est.
$-0.08
Q1'23
Missed
by $0.02
Q4'22
Beat
by $0.04
Q3'22
Missed
by $0.13
Q2'22
Beat
by $0.01
The last earnings report on May 03 showed earnings per share of -20 cents, missing the estimate of -19 cents. With 80.25K shares outstanding, the current market capitalization sits at 1.88B.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Align Technology (NASDAQ:ALGN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 6.33B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 1%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 21%. NEPH experienced the highest price growth at 71%, while ANPCY experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 36%. For the same stocks of the Industry, the average monthly volume growth was 53% and the average quarterly volume growth was -69%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 68
Price Growth Rating: 56
SMR Rating: 83
Profit Risk Rating: 85
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutic and predictive medicine products

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
320 Wakara Way
Phone
+1 801 584-3600
Employees
2600
Web
https://www.myriad.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGOCX16.520.25
+1.54%
Goldman Sachs Mid Cap Growth C
USBNX22.030.28
+1.29%
Pear Tree Polaris Small Cap Ord
CAFFX34.170.29
+0.86%
American Funds AMCAP 529F1
ACAEX11.85N/A
N/A
American Century International Gr G
MVGBX14.63N/A
N/A
MFS Low Volatility Global Equity B

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with NTRA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then NTRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
+4.71%
NTRA - MYGN
53%
Loosely correlated
+4.63%
IQV - MYGN
53%
Loosely correlated
+1.05%
EXAS - MYGN
52%
Loosely correlated
+2.77%
RVTY - MYGN
51%
Loosely correlated
+0.30%
ILMN - MYGN
51%
Loosely correlated
+1.24%
More